A Review on Essentials of Regulatory Affairs: Drug Approvals, Compliance, and Global Regulations

Eppanoori shivani, Ashok Gorja, Durga Pani Kumar Anumolu, Syed Sara Afreen, Hirijana Upendra, Bandaru Aashritha*

Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad - 500090, Telangana, India

Abstract

Regulatory affairs play a crucial role in the pharmaceutical industry by ensuring drug safety, efficacy, and compliance with global regulations. This syllabus provides an in-depth understanding of regulatory authorities, their guidelines, and the drug approval process in major markets, including India, the USA, the EU, Canada, Japan, and Australia. It covers ICH guidelines, CTD/eCTD submissions, and key regulatory documents such as the Orange Book and Drug Master Files. Additionally, it explores clinical trial regulations, institutional review boards, and sponsor responsibilities. This comprehensive course equips students with essential knowledge to navigate regulatory frameworks and contribute effectively to pharmaceutical compliance.

Keywords: Regulatory affairs, pharmaceutical industry, drug safety, drug efficacy, global regulations, regulatory authorities, drug approval process, ICH guidelines, CTD, eCTD, Orange Book, Drug Master Files, clinical trial regulations, institutional review boards, sponsor responsibilities, pharmaceutical compliance.

Corresponding Author: Bandaru Aashritha (bandaruaashu24@gmail.com)

INTRODUCTION

Regulatory affairs is a profession developed from the desire of governments to protect public health by controlling the safety and efficacy of products in areas including pharmaceuticals, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines, and by the companies responsible for the discovery, testing, manufacture and marketing of these products wanting to ensure that they supply products that are safe and make a worthwhile contribution to public health and welfare. A new class of professionals emerged to handle these regulatory matters for companies.

Drug regulatory affairs involve developing and submitting regulatory applications to obtain marketing authorization for drugs and medical devices. Professionals ensure compliance with regulatory guidelines, ensuring products are safe, effective, and of high quality. Their role is crucial in securing market approval and ongoing safety monitoring.

It plays a vital role in the drug development process, ensuring thorough testing and evaluation before market approval. Regulatory oversight is essential to maintaining public health and safety.

Roles and Responsibilities:

1. Regulatory Affairs plays a key role in the pharmaceutical industry: from drug development to commercialization, especially during drug development: a lengthy, complex, and extremely costly but necessary process.
2. The regulatory department is responsible for a lot. First, they have to ensure manufacturers are in compliance with any applicable global legislative and regulatory requirements. And these steps need to be followed at each stage of the development process, so all the way from research and development to the pre-clinical phase through the clinical phase, and then followed by marketing and post-marketing.
3. Along with the drug development process, there are many times where regulatory submissions are required to move on to the next phase of the drug development process. Next, regulatory affairs professional is also responsible for keeping track of all the different updated legislative not only in the countries that the company might be in but globally which means, basically, anywhere that company is looking to distribute its products.

4. The Regulatory Affairs department provides strategic and technical advice at the highest level in such companies. In this way, they make a significant contribution, both commercially and scientifically, to the success of a development program and the company as a whole.

5. Early in the development process, at the research stage, it is critical to get regulatory affairs involved to ensure that an appropriate Clinical Development Strategy is developed with the goal of a carefully planned series of clinical trials, ranging from first-in-human Phase I to Phase II "proof of concept" and crucial Phase III trials for registration purposes.

6. Once the drug discovery phase, during which potentially interesting compounds are tested for their non-clinical characteristics, the clinical phases (early to late phase) are initiated to further test the safety and efficacy of the drug candidate. After successful clinical trials, marketing approval for a medicinal product must be sought through the submission of a marketing authorization.

7. When the marketing authorization is granted by the competent authorities, commercialization of the medicinal product can begin, but through variation post-approval amendments will continue to be submitted by the regulatory affairs team, to ensure the dossier being approved by regulators is always updated.

8. The role of an experienced regulatory affairs team in the approval process will be important to maintain the goal of timely commercialization of the product.

9. Many pharmaceutical companies are looking for external RA team members with specific expertise to ensure that products are developed, manufactured, and controlled at all levels of expected quality, safety, and efficacy. Experienced consultants to ensure all filing and submission goals are met, with high quality and within expected timelines.



Fig no:1 Roles and responsibilities

Drug regulatory authorities in India:

The Central Drugs Standard Control Organization (CDSCO), headquartered in New Delhi, regulates pharmaceuticals, medical devices, and cosmetics in India. It oversees drug approvals, clinical trials, import registrations, licensing, and market surveillance. CDSCO handles drug bans, testing, certification, and issues guidelines on technical matters. It collaborates with the Drugs Controller General of India (DCGI) and related bodies for enforcement.

Functions of CDSCO:

CDSCO approves new drugs, clinical trials, and imports, and licenses blood banks, vaccines, medical devices, and diagnostics. It participates in WHO GMP certification, bans unsafe drugs, and grants licenses and NOCs for exports. CDSCO also conducts drug testing, publishes the Indian Pharmacopoeia, and provides technical guidance. Additionally, it proposes amendments to the Drugs & Cosmetics Act.



Fig No:2 Organization chart of CDSCO

Drug Regulatory Authorities in Europe (EU):

The European medicines regulatory system involves around 50 authorities from 30 EEA countries, the European Commission, and EMA. EMA and member states collaborate in assessing new medicines, monitoring safety, and handling public health emergencies. They share information on side effects, clinical trials, inspections, and compliance with GCP, GMP, GDP, and GVP. EMA offers a unified process for EU-wide market authorization.

THE ROLE OF EMA:

Established in 1995, EMA evaluates and supervises innovative medicines in the EU. It ensures efficient use of scientific resources for pharmacovigilance and regulatory oversight. Experts contribute through scientific committees, advisory groups, and national assessment teams.



Fig No:2 Organization chart of Europe

REGULATORY AUTHORITIES OF U.S:

The FDA protects public health by ensuring the safety, efficacy, and security of drugs, medical devices, food, cosmetics, and radiation-emitting products. It regulates tobacco to reduce use among minors and advances medical innovations for better public health. The FDA also provides science-based information and supports counterterrorism by securing the food supply and addressing emerging health threats. In general, FDA regulates:

Products	**Includes**
Foods	Dietary Supplements Bottled water Food Additives Infant Formulas Other Food Products
Drugs	Prescription Drugs Non-Prescription Drugs
Biologics	Vaccines for Humans Blood and Blood Products Cellular and Gene Therapy Products Tissue and Tissue Products Allergenics
Medical Devices	Simple items like tongue depressors and bedpans Complex Technologies such as heart pacemakers Dental Devices Surgical Implants

Electronic Products that give off radiation	Microwave Ovens X-Ray equipment Laser Products Ultrasonic therapy Equipment Mercury Vapor Lamps Sunlamps
Cosmetics	Skin Moisturizers and Cleansers Nail Polish and Perfume
Veterinary	Livestock Feed Pet foods Veterinary Drugs and Devices
Tobacco	Cigarettes Cigarette Tobacco roll-your-own tobacco Cigars Hookah

Table no.1 FDA regulations

Various U.S. agencies regulate consumer safety and advertising: the FTC stops deceptive practices; TTB oversees alcohol production and distribution; CPSC ensures the safety of consumer products; DEA enforces controlled substances laws; and USDA's FSIS regulates meat and poultry safety. The FDA's Office of Inspections and Investigations (OII) leads inspections, investigations, and emergency responses, supporting regulatory decision-making.



Fig No. 4: Organization Chart of U.S FDA

Regulatory Authorities in Canada:

Health Canada ensures the safe and effective use of drugs and health products. Strict regulations for food, veterinary, pharmaceutical, and biological drugs create challenges for foreign manufacturers entering the market.

Those Regulatory bodies include:

- Health Canada's Health Products and Food Branch (HPFB) – for Food, Health and Veterinary
- Therapeutic Product Directorate (TPD) – for Pharmaceuticals and Medical Devices
- Biologics and Genetic Therapies Directorate (BGTD) – for Biological and Radiopharmaceutical drugs

HPFB:

The Health Products and Food Branch (HPFB) safeguards Canadians' health by minimizing risks and ensuring the safety of health products and food. It evaluates product safety, implements nutrition policies, and provides evidence-based information to support informed decisions. HPFB also anticipates and addresses public health issues, promoting overall well-being while maintaining regulatory standards for safety, quality, and efficacy in health products and food.

TPD:

The Pharmaceutical Drugs Directorate (PDD) regulates prescription drugs in Canada, ensuring their safety, efficacy, and quality under the Food and Drugs Act. PDD reviews scientific data, clinical trials, and adverse reactions, assesses drug risks and benefits, and facilitates access to non-marketed drugs when necessary. It provides science-based information to help Canadians make informed medical decisions.

BGTD:

Health Canada's Biologic and Radiopharmaceutical Drugs Directorate (BRDD) regulates biological drugs, radiopharmaceuticals, and human cells, tissues, and organs. It oversees vaccines, radioactive drugs, and compliance with the Assisted Human Reproduction Act and its regulations to ensure safety and quality for Canadians.



Fig No.5 Organization chart of Canada.

Regulatory Authorities in Japan:

Japan's pharmaceutical regulatory system, led by the PMDA and MHLW, emphasizes safety, efficacy, and quality through strict standards and comprehensive reviews. Detailed documentation and robust clinical trial data are essential for compliance. CMIC Group provides expertise in navigating these regulations, ensuring smooth communication with authorities, and helping overseas sponsors meet Japan's complex requirements.

Regulatory Authorities for NDA Approval

PMDA (Pharmaceuticals and Medical Devices Agency): Conducts review of application dossier and conducts compliance investigations

- MHLW (Ministry of Health Labor and Welfare)： Approval Authority
- Expert Advisory Meeting
- Drugs Committee.



Fig No.6 Organization chart of Japan.

Regulatory Authorities in Australia:

The Therapeutic Goods Administration (TGA), part of Australia's Department of Health, ensures therapeutic goods are safe and fit for use. Using a risk-based approach, the TGA rigorously assesses higher-risk products before including them in the Australian Register of Therapeutic Goods (ARTG). It monitors approved products, addressing emerging risks or benefits, and may take regulatory actions, including market withdrawal.

Examples of therapeutic goods include:

The TGA regulates medicines, medical devices, vaccines, biologicals, blood products, sunscreens, sterilant, disinfectants, and menstrual products like tampons and cups.

Responsibilities of the TGA:

The key roles and responsibilities of the TGA are as follows:

1. The TGA regulates therapeutic goods in Australia, including medicines, vaccines, medical devices, and blood products, overseeing their supply, import, export, production, and advertising.
2. It enforces the *Therapeutic Goods Act 1989*, ensuring the quality, safety, and efficacy of approved and unapproved therapeutic goods, while issuing manufacturing permits and certifications.
3. The TGA conducts pre-market assessments, post-market monitoring, and standard enforcement, ensuring compliance by both Australian and international manufacturers.



Fig No.7 Organization chart of Australia.

ICH: INTERNATIONAL COUNCIL FOR HORMONISATON OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE

The International Council for Harmonization (ICH) unites regulatory authorities and the pharmaceutical industry to harmonize drug registration globally. Founded in 1990, ICH develops Guidelines through scientific consensus, ensuring safe, effective, high-quality medicines are registered efficiently. Its success relies on regulatory commitment to implement Guidelines, categorized into four key areas for streamlined drug development and approval.

Quality Guidelines:

Harmonization achievements in the Quality area include pivotal milestones such as the conduct of stability studies, defining relevant thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management.

Guideline	Area Covered
Q1A-Q1F	Stability
Q2	Analytical Validation
Q3A-Q3D	Impurities
Q4A-Q4B	Pharmacopoeias
Q5A-Q5E	Quality of Biotechnological Products
Q6A-Q6B	Specifications
Q7	Good manufacturing Practice
Q8	Pharmaceutical Development
Q9	Quality Risk Management
Q10	Pharmaceutical Quality System
Q11	Development and Manufacture of Drug Substance
Q12	Lifecycle Management
Q13	Continues Management of Drug Substances and Drug Products
Q14	Analytical Procedure Development

Table No.2 Quality Guidelines

Safety Guidelines:

ICH has produced a comprehensive set of safety Guidelines to uncover potential risks like carcinogenicity, genotoxicity and reprotoxicity. A recent breakthrough has been a non-clinical testing strategy for assessing the QT interval prolongation liability: the single most important cause of drug withdrawals in recent years single most important cause of drug withdrawals in recent years.

Guidelines	**Area Covered**
S1A-S1C	Carcinogenicity Studies
S2	Genotoxicity Studies
S3A-S3B	Toxicokinetics and Pharmacokinetics
S4	Toxicity Testing
S5	Reproductive Toxicology
S6	Biotechnological Products
S7A-S7B	Pharmacological Studies
S8	Immunotoxicology Studies
S9	Nonclinical Evaluation for Anticancer Pharmaceuticals
S10	Photo safety Evaluation
S11	Nonclinical Pediatric Safety

Table No.3 Safety Guidelines

Efficacy Guidelines:

The work carried out by ICH under the Efficacy heading is concerned with the design, conduct, safety and reporting of clinical trials. It also covers novel types of medicines derived from biotechnological processes and the use of pharmacogenetics/genomics techniques to produce better targeted medicines.

Guidelines	**Area Covered**
E1	Clinica Safety for Drugs Used in Long-term Treatment
E2A-E2F	Pharmacovigilance
E3	Clinical Study Reports
E4	Dose-Response Studies
E5	Ethnic Factors
E6	Good Clinical Practice
E7	Clinical Practice in Geriatric Population
E8	General Considerations for Clinical Trials
E9	Statistical Principles for Clinical Trials
E10	Choice of Control Group in Clinical Trials
E11-E11A	Clinical Trails in Pediatric Population
E12	Clinical Evaluation by Therapeutic Category
E14	Clinical Evaluation of QT
E15	Definitions in Pharmacogenetics / Pharmacogenomics
E16	Qualification of Genomic Biomarkers
E17	Multi-Regional Clinical Trials
E18	Genomic Sampling
E19	Safety Data Collection
E20	Adaptive Clinical Trials

Table No.4 Efficacy Guidelines

MULTIDISCIPLINARY GUIDELINES (M):

Those are the cross-cutting topics which do not fit uniquely into one of the Quality, Safety and Efficacy categories. It includes the ICH medical terminology (MedDRA), the Common Technical Document (CTD) and the development of Electronic Standards for the Transfer of Regulatory Information (ESTRI).

Guidelines	**Area Covered**
M1	MedDRA Terminology
M2	Electronic Standards
M3	Nonclinical Safety Studies
M4	Common Technical Document
M5	Data Elements and Standards for Drug Dictionaries
M6	Gene Therapy
M7	Mutagenic impurities
M8	Electronic Common Technical Document i.e., eCTD
M9	Biopharmaceutics Classification System-based Biowaivers
M10	Bio-analytical Method Validation
M11	Clinical electronic Structured Harmonized Protocol i.e., CeSHarP
M12	Drug Interaction Studies

Table No.5 Multidisciplinary Guidelines

QSEM Guidelines

Harmonization achievements in the Quality area include pivotal milestones such as the conduct of stability studies, defining relevant thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management.

INTRODUCTUON TO CTD

M4: Common Technical Document

This guideline provides a standardized structure for creating the Common Technical Document (CTD) for regulatory submissions. Adopting a common format will streamline the submission process, saving time and resources, while enhancing communication with regulatory authorities. It focuses on organizing information for registration applications for new pharmaceuticals, including biotechnology products. While it does not mandate specific studies, it offers a framework for presenting data. Applicants should maintain the overall CTD organization but can modify formats in the Nonclinical and Clinical Summaries for better clarity and comprehension**.**

GENERAL PRINCIPLES

The Common Technical Document must display information in a clear and transparent manner for efficient review. Text and tables should be designed to fit both A4 (EU, Japan) and 8.5 x 11” (U.S.) paper sizes, with a wide enough left margin to ensure no content is hidden. A readable font, like 12-point Times New Roman, should be used for text and tables. Pages must be numbered, and acronyms should be explained when first used. References should comply with the latest ICMJE guidelines.

ORGANISATION OF THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

The Common Technical Document is organized into five modules. Module 1 is region specific. Modules 2, 3, 4, and 5 are intended to be common for all regions. Conformance with this guideline should ensure that these four modules are provided in a format acceptable to the regulatory authorities.

Module 1: Administrative Information and Prescribing Information

This module should contain documents specific to each region: for example, application forms or the proposed label for use in the region. The content and format of this module can be specified by the relevant regulatory authorities.

1.1Table of Contents of the Submission Including Module 1

1.2 Documents Specific to Each Region (for example, application forms, prescribing information).

Module 2: Common Technical Document Summaries

Module 2 should begin with a general introduction to the pharmaceutical, including its pharmacologic class, mode of action, and proposed clinical use. In general, the Introduction should not exceed one page.

Module 2 should contain 7 sections in the following order:

2.1 Common Technical Document Table of Contents (Modules 2-5)

2.2 CTD Introduction

2.3 Quality Overall

2.4 Nonclinical Overview

2.5 Clinical Overview

2.6 Nonclinical Written and Tabulated Summaries

Pharmacology

Pharmacokinetics

Toxicology

2.7 Clinical Summary

Biopharmaceutic Studies and Associated Analytical Methods

Clinical Pharmacology Studies

Clinical Efficacy

Clinical Safety

Literature References

Synopses of Individual Studies

Module 3: Quality

Information on Quality should be presented in the structured format described in Guideline M4Q

3.1 Table of Contents of Module 3

3.2 Body of Data

3.3 Literature References

Module 4: Nonclinical Study Reports

The nonclinical study reports should be presented in the order described in Guideline

4.1 Table of Contents of Module 4

4.2 Study Reports

4.3 Literature References

Module 5: Clinical Study Reports

The human study reports and related information should be presented in the order described in Guideline M4E.

5.1 Table of Contents of Module 5

5.2 Tabular Listing of All Clinical Studies

5.3 Clinical Study Reports

5.4 Literature References

The Common Technical Document (CTD) standardizes Quality, Safety, and Efficacy data, streamlining regulatory reviews and enabling harmonized electronic submissions. This eliminates the need for reformatting across ICH authorities, enhancing efficiency for industries and regulators.



Fig No.8 CTD Triangle

ELECTRONIC COMMON TECHNICAL DOCUMENT (eCTD)

The Electronic Common Technical Document (eCTD) streamlines regulatory submissions between pharmaceutical companies and regulators. Introduced in 2003, it simplifies the submission process, reducing costs, paper usage, and review time. While regional differences exist, standardization is enhancing consistency. Preparing eCTD-compliant documents avoids delays caused by reformatting. As an electronic version of the Common Technical Document (CTD), eCTD improves the efficiency of drug approvals globally, including in the US, EU, Canada, and Japan.

The main technical components include:

- A required high-level folder structure
- An Extensible Markup Language (XML) "backbone" file that contains metadata about the content files and lifecycle instructions for the receiving system
- An optional lower-level folder structure (recommended folder names are provided in the eCTD specification modules)
- Associated document type definitions (DTDs) and style sheets to aid in document presentation and navigation.

Benefits of Implementing eCTD:

Standardizing electronic submissions promotes greater consistency for both regulators and organizations. Main advantages include:

- Faster reviews through tools that allow searching, copying, and pasting text.
- More efficient processes with the involvement of multiple reviewers.
- Simplified document reuse across different regions for sponsors.
- Enhanced ability to organize, prepare, and manage submission content.
- Lower storage costs associated with paper dossiers.
- Optimized workflows and improved collaboration between development, regulatory, and marketing teams.

Modules of eCTD:

The eCTD has five modules divided into two categories:

1. **Regional Module** (Module 1) - Includes administrative and prescribing information, specific to each region (USA, Europe, Japan).
2. **Common Modules** (Modules 2-5) - Harmonized across regions:
    - Module 2: Technical document summaries.
    - Module 3: Quality.

- Module 4: Nonclinical study reports.
- Module 5: Clinical study reports.

IND (Investigation of New Drug)

An Investigational New Drug Application (IND) is a request submitted by a Sponsor to the FDA, seeking permission to conduct clinical trials on unapproved drugs. The purpose of the IND is to enable Sponsors to begin human trials and to allow the shipment of the drug across state lines for these studies.

Types of INDs

INDs fall into two categories:

Commercial IND: Used when a Sponsor plans to bring a drug to market, including non-profits aiming to commercialize the drug. The process is more complex and time-consuming than a Research IND.

Research IND: Used to demonstrate the efficacy of an already approved drug for a new indication. Submitted by physicians, it involves fewer investigators and is typically conducted at a single site, with a simpler process than a Commercial IND.

IND Filing Requirements

 FDA **Forms**: 1571 (cover letter), 1572 (investigator statement), and 3674 (certification for ClinicalTrials.gov registration).

 Documents: Table of contents, introductory statement, general investigational plan, and investigator's brochure.

 Protocols: Study protocols, investigator and facility data, and IRB details.

 CMC **Data**: Chemistry, manufacturing, and control information, including environmental assessment.

 Nonclinical **Data**: Pharmacology and toxicology information.

 Clinical **Data**: Previous human experience.

 Additional **Support**: Any further information to back the IND filing.

IND Application Process

The IND application allows manufacturers to seek FDA approval for human clinical trials, assessing a drug's safety and effectiveness. If successful, the sponsor may submit an NDA for public sale approval.

The steps include:

1. **Preclinical Testing**: Conduct lab and animal studies to assess safety and efficacy.

2. **Prepare Application**: Compile preclinical data, manufacturing details, and clinical trial protocols.
3. **Submit Application**: Submit the IND electronically or by mail to the FDA.
4. **FDA Review**: The FDA evaluates the scientific validity, ethics, and safety of the trial.
5. **Conduct Clinical Trials**: If approved, conduct human trials to test safety and efficacy.
6. **Annual Reporting**: Submit safety updates and protocol changes to the FDA annually.

NDA (New Drug Application):

The NDA includes comprehensive data demonstrating a drug's safety, efficacy, composition, manufacturing, labeling, and trial results. After preclinical and clinical trials confirm safety and effectiveness, pharmaceutical companies submit an NDA to the FDA. Approval allows the drug to be legally marketed in the United States.

The goals of the NDA are to supply sufficient information for FDA reviewers to make key decisions, including:

- Assessing whether the drug is safe and effective for its intended use(s) and if its benefits outweigh the risks.
- Determining if the proposed labelling (package insert) is suitable and what it should include.
- Evaluating whether the manufacturing methods and quality control measures are adequate to maintain the drug's identity, strength, quality, and purity.

The ANDA Submission Process:

An Abbreviated New Drug Application (ANDA) is submitted to the U.S. Food and Drug Administration (FDA) to seek approval for a generic drug. It provides evidence that the generic drug is identical to an already approved brand-name drug in terms of active ingredients, dosage form, strength, administration route, quality, and performance. Once approved, the applicant can produce and market the generic drug as a safe, effective, and more affordable alternative. The ANDA is a critical part of the generic drug approval process in the U.S., designed to lower drug costs, reduce

development time, and improve the drug's bioavailability compared to the reference drug.

Here's a general overview of the steps involved in submitting an ANDA for FDA approval:

1. Pre-ANDA Preparation: The sponsor gathers detailed information about the reference listed drug (RLD), including its chemical composition, pharmacological properties, formulation, labelling, and regulatory history. This ensures the generic drug's equivalence to the RLD.
2. ANDA Preparation: The sponsor compiles the ANDA, providing evidence that the generic drug is chemically, pharmacologically, and clinically similar to the RLD. It also includes details on the manufacturing process, quality control measures, and proposed labelling.
3. ANDA Submission: The completed ANDA is submitted electronically to the FDA's Centre for Drug Evaluation and Research (CDER) through the FDA's electronic submissions gateway.
4. FDA Review: The FDA evaluates the ANDA to determine if it meets the regulatory standards for approval. This process usually takes around 30 months but can be expedited for drugs targeting serious conditions or unmet medical needs.
5. FDA Decision: After review, the FDA either approves or rejects the ANDA. Approval permits the sponsor to market the generic drug.

BLA:

The Biologics License Application (BLA) is a request to obtain permission to introduce or transport a biologic product into interstate commerce (21 CFR 601.2). Regulated under 21 CFR 600-680, the BLA is submitted by any legal entity or person involved in the manufacturing process or applying for a license, and takes responsibility for ensuring compliance with product and establishment standards.

Non-clinical Overview:

The non-clinical development phase evaluates a therapy's safety, success potential, and scientific foundation before clinical trials. It also addresses non-medical goals, such as intellectual property rights and producing trial-ready compounds. This complex,

regulatory-driven phase involves various studies to ensure readiness for clinical development.

Some key CMC steps in nonclinical trials are:

- To determine the dose and administration (how the medicine is given, e.g. the dose or how often it is given).
- To describe the physico-chemical characteristics (traits) of the medicinal product in detail.
- To test the stability & purity of the medicinal product.
- To develop and validate the methods used to quantify the active substance in body fluids such as blood, plasma, or urine. This is done in activity and side effect studies.
- To develop a prototype of the medicine which will be used in the clinic.

There are three types of non-clinical development studies:

1. Pharmacodynamic studies

2. Pharmacokinetics studies

3. Toxicology studies

Clinical Trails Overview:

Clinical research plays a crucial role in advancing our knowledge and understanding of human health and disease, as well as in the development of innovative and effective treatments. Clinical trials are a fundamental element of evidence-based medical research.

Clinical trials are research studies conducted with people, including healthy volunteers or patients, to evaluate the safety and effectiveness of new treatments. A ‘Treatment’ in this context means:

1.A medicine

2.A medical device

3.A surgical procedure

4.A test for diagnosing an illness

5.A clinical trial can also compare whether a new treatment is better than existing alternatives.

How are clinical trials conducted?

Approval for a clinical trial requires submitting a Clinical Trial Application (CTA) to regulatory authorities and obtaining a review from a Research Ethics Committee (REC). Clinical trials in the U.S. and EU adhere to regulations and the Good Clinical Practice (GCP) guidelines established by the International Conference on Harmonisation (ICH-GCP). GCP defines the roles and responsibilities of investigators, monitors, sponsors, and ethics committees, addressing the monitoring, reporting, and archiving of trial data, along with key documents such as the Investigator's Brochure.

Who conducts medicine clinical trials and why?

Clinical trials involve several key participants, each with distinct responsibilities:

Sponsor: Usually a company, university, or hospital that organizes and funds the trial. Sponsors may engage contract research organizations (CROs) to assist with logistics.

Investigator: The physician(s) responsible for conducting the trial, especially in multi-centre studies.

Sponsors, whether private entities or government institutions, conduct trials to collect data for regulatory approval and marketing. They may also collaborate on research addressing public health needs or investigating issues of interest to patients and healthcare systems that lack commercial incentives.

Phases of Clinical Trials:

 Phase I Trials: Assess the safety of a new treatment, determine the optimal method of administration, and identify any indications of cancer response.

 Phase II Trials: Evaluate whether a specific type of cancer responds to the new treatment.

 Phase III Trials: Compare the effectiveness of the new treatment against standard treatment options.

 Phase IV Trials: Gather additional data on long-term benefits and side effects of the treatment.

Clinical Trial Protocol Development:

A research protocol is a detailed document outlining the background, rationale, objectives, design, methods, statistical considerations, and organizational framework of a clinical research study. As per the ICH Good Clinical Practice guidelines, it should cover the following key topics:

- **Title Page & General Information**
- **Background & Objectives**: Study rationale and purpose.
- **Study Design & Subject Criteria**: Design, selection, and exclusion of participants.
- **Treatment & Assessments**: Treatment methods, efficacy, and safety evaluations.
- **Adverse Events & Study Discontinuation**
- **Statistics & Quality Assurance**: Data analysis and quality control measures.
- **Ethics, Data Management & Publication**: Ethical considerations, recordkeeping, and publication policies.
- **Timetable, References & Appendices**: Study schedule, supporting materials, and references.

Institutional Review Board:

The Institutional Review Board (IRB) is a federally required body that oversees human research to ensure the protection of participants' rights and well-being. Researchers must secure IRB approval for studies involving people, data, or specimens. Although the approval process may appear difficult, the IRB's role is to support researchers in conducting ethical, participant-centered research.

Role and Purpose of IRBs:

An IRB is a formally recognized group established by federal regulations to review and oversee biomedical research involving human participants. Under US Food and Drug Administration (FDA) regulations, the IRB has the authority to approve, request modifications for approval, or reject research. The IRB's review process is essential for safeguarding the rights and welfare of human research participants.

Orange Book:

The Orange Book, formally *Approved Drug Products with Therapeutic Equivalence Evaluations*, lists FDA-approved drugs proven safe and effective. It excludes drugs with withdrawn safety or efficacy approvals but may include those under regulatory action. The list ensures therapeutic equivalence and supports informed prescribing and substitution decisions.

Understanding the Orange Book:

The FDA approves drugs after double-blind randomized trials. Early phases assess safety, while Phase 3 trials test safety and efficacy on larger samples. Successful drugs are added to the Orange Book and approved for use.

PURPLE BOOK

The Purple Book is an FDA database listing all licensed biological products regulated by the Centre for Drug Evaluation and Research (CDER) and the Centre for Biologics Evaluation and Research (CBER). It includes biosimilars, interchangeable products, reference products, allergenic products, cellular and gene therapies, hematologic products, and vaccines. Initially available as separate CDER and CBER lists, the unified Purple Book was launched online in September 2014 and is periodically updated.

The database provides critical information about biologics, such as licensing dates under section 351(a) of the PHS Act, reference product exclusivity evaluations, and determinations of bio similarity or interchangeability. Biosimilars and interchangeable products are grouped under their respective reference products to enhance usability.

Additional details include BLA numbers, non-proprietary and proprietary product names, market approval dates, first licensure dates, biosimilar or interchangeable status, reference product expiry dates, and market withdrawal status. This comprehensive resource facilitates informed decision-making regarding licensed biological products.

The Purple Book database contains information for multiple users

- **Patients and General Public**: Use the Purple Book's *Simple Search* to find information about biological products they take or may be prescribed, including FDA-approved biosimilars and interchangeable products.

 Healthcare Providers: Use the *Simple Search* to view associated products for prescriptions and the *Advanced Search* for detailed queries like strength, dosage forms, or presentations. Product labels provide additional prescribing information.

 Manufacturers and Researchers: Use the *Advanced Search* to view, sort, and download detailed information in table format (Excel, CSV, or PDF).

DRUG MASTER FILE:

A Drug Master File (DMF) is a confidential document submitted voluntarily to regulatory authorities, providing detailed information about facilities, processes, or materials used in manufacturing, processing, or storing drugs. It supports applications like INDs, NDAs, ANDAs, or export approvals. Known as EDMF/ASMF in Europe and US-DMF in the U.S., submission is not legally required.

DMFs:

DMFs enable third-party reference to materials without disclosure, don't replace applications like INDs or NDAs, aren't formally approved by the FDA, and are accessed by FDA reviewers only when cited in another application.

Discussion

Regulatory affairs (RA) is a critical function within the pharmaceutical industry that ensures compliance with laws, regulations, and standards governing the development, manufacturing, and marketing of pharmaceutical products. It outlines the importance of regulatory guidance documents, rules, and regulations in guiding regulatory compliance efforts within the industry. Additionally, the article discusses recent amendments in pharmaceutical regulations, highlighting the evolving nature of regulatory requirements and the need for industry adaptation.

Regulatory authorities play a pivotal role in overseeing and enforcing regulatory requirements to safeguard public health and ensure the quality, safety, and efficacy of pharmaceutical products. It provides an overview of regulatory authorities in key regions such as India, the USA, the EU, Canada, Japan, and Australia. It outlines the organizational structure of these regulatory agencies, including their roles, responsibilities, and key functions in regulating pharmaceutical products.

The regulatory approval process involves the submission and review of applications for marketing authorization of pharmaceutical products. In this section, we discussed the approval process and timelines associated with key regulatory submissions, including Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), and Biological License Application (BLA). It outlines the requirements and milestones involved in each stage of the approval process, highlighting the importance of timely and compliant submissions to expedite market access for pharmaceutical products.

It explains the significance of regulatory reference documents such as the Orange Book (for drugs) and the Purple Book (for biological products) in providing information on approved products and their regulatory status. Additionally, we discussed about the Federal Register and the Code of Federal Regulations as key sources of regulatory information in the USA. Other topics covered include Drug Master Files (DMF), annual reports, and changes to approved NDA/ANDA submissions, emphasizing the importance of regulatory compliance and documentation throughout the product lifecycle.

Conclusion

DRA is a rewarding and approachable field that include legal and scientific both dynamic aspects of new drug development. Regulatory governing bodies have been formed all around the world to ensure that medicines for human use satisfy global standards of quality, effectiveness, and safety. For example, FDA, TGA, CDSCO, EMEA, and others. It includes legislation that requires drugs to be trailed, manufactured, tested and developed in according to guidelines given by authority, so that they are safe and patients will be well healthy and protected. In this practice school we reviewed and provided a comprehensive overview of regulatory affairs, regulatory authorities, regulatory approval processes, and general regulatory concepts in the pharmaceutical industry. By covering these essential topics, the work aims to enhance understanding and awareness of regulatory requirements among stakeholders involved in pharmaceutical product development, manufacturing, and commercialization.

References

1. Rahalkar H. Historical Overview of Pharmaceutical Industry and Drug Regulatory Affairs. Pharmaceutical Regulatory Affairs, 2007; S11:002.
2. Badjatya J.K. International Journal of Drug Regulatory Affairs: IJDRA Publishing Group; 2013.
3. Praneeth P. SSRG International Journal of Pharmacy and Biomedical Engineering 2016; 3(1):1-2.
4. Douglas JP, David SM. Textbook of FDA Regulatory Affairs. A Guide for Prescription Drugs, Medical Devices, and Biologics, 2nd edition; 2008.
5. Hasumati Rahalkar. Historical Overview of Pharmaceutical Industry and Drug Regulatory Affairs, Pharmaceutical Regulatory Affairs: Open Access; 2012.
6. Sri Harsha Y. Role of regulatory affairs in a pharmaceutical industry. International Journal of Pharmaceutical Research and Bioscience 2017; 6(2):170-177.
7. Priyanka SB, Vijay GR, Lahu DH. Review on regulatory affairs in pharmaceutical industries; Journal of Emerging Technologies and Innovative Research 2020; 7(1):66-73.
8. Rajesh D, Chirag Patil. An overview of regulatory affairs in pharmaceutical industry. International Journal of Universal Pharmacy and Biosciences 2020; 9(4): 158-168.
9. Geetanjali Sengar, Pranab Tripathy. Pharmaceutical Regulatory Agencies and Organizations around the World: Scope and Challenges in Development. JETIR Research Journal.
10. Srivastava DA. Country-level report on the pharmaceutical sector in India. Report commissioned by DFID, UK.
11. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty seventh Report. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908).
12. Guide to good storage practices for pharmaceuticals, WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty seventh Report. Geneva, World Health Organization; 2003 (WHO Technical Report Series, No. 908, Annex 9).

13. WHO Expert Committee on Specifications for Pharmaceutical Preparations; Thirty-eighth Report, Geneva, World Health Organization; 2004 (Technical Report Series, No. 917).
14. Good trade and distribution practices for pharmaceutical starting materials. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty eighth Report. Geneva, World Health Organization; 2004 (WHO Technical Report Series, No. 917, Annex 2).
15. Quality Assurance of Pharmaceuticals, A compendium of guidelines and related materials, Volume 1. Geneva, World Health Organization; 1997.
16. Quality Assurance of Pharmaceuticals, A compendium of guidelines and related materials, Good manufacturing practices and inspection; Volume 2 (updated version), Geneva, World Health Organization; 2004
17. Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (Generic) Products A Manual for a Drug Regulatory Authority, Geneva, World Health Organization; 1999 (Regulatory Support Series, No.5, WHO/DMP/RGS/98.5).
18. A Model Quality Assurance System for Prequalification, Procurement, Storage and Distribution of Pharmaceutical Products. Geneva, World Health Organization; 2003.
19. Managing Drug Supply, The selection, procurement, distribution, and use of pharmaceuticals. Management Sciences for Health in collaboration with World Health Organization, 2nd Ed. Connecticut, USA. Kumarian Press, Inc.; 1997.
20. Guidelines on Good Distribution Practice of Medicinal Products for Human Use (94/C63/03), European Agency for Evaluation of Medicinal Products, Directive 92/25/EEC of 31 March 1992.
21. Janjal, V., Dhamodkar, S., Jadhao, Y., Manmode, S., Pawat, A. and Khandelwal, H., 2021. Review article on Recent drug regulatory affairs and CTD module progress review for submission of pharmaceutical product. GSC Biological Pharmaceutical Sci., 16(3), pp.200-221.
22. Kumar, S., Panwar, R. and Singh, U., 2013. “Regulatory affairs in the pharmacy curriculum”,Int.J.Res.Dev.Pharm.L.Sci., 2(6), pp.690-698.
23. Dakme, P., Dey, B. and Amin, R., 2020. Role of regulatory affairs in the BRICS countries. World Journal of Pharmacy and Pharmaceutical Science, 9(10), pp.515-533.

24. Chandra, A. and Kumar, B., 2016. A comparative study of the drug approval process in USA, INDIA, JAPAN AND EUROPE. World journal of pharmaceutical Research, 6(1), pp.311-322.
25. Chakraborty, K. and Yadav, K., 2018. Drug approval process in US, EUROPE and India and its regulatory requirements: A Review. International journal of Drug regulatory Affairs, 6(3), pp.31-39.
26. Kumar, B., 2013. Overview of Drug Regulatory Affairs and Regulatory Profession. International journal of Drug regulatory affairs, 1(1), pp.1-4.
27. Sihorwala, Z., 2017. Drug Regulatory Affairs. Pharma Times, 49(05), pp.28-30
28. Raj, R., Pattanaik, P. and Roy, H., 2015. The Dynamics of Global pharma Regulatory Affairs system. Indo American Journal of pharmacy, 1(1), pp.28-34.
29. Kumar, D., Bhowmik, D., Bhanot, R. and Goswami, S., 2020. A Textbook of Industrial Pharmacy - II. 1st ed. Pune: Nirali Prakashan, pp. Unit 3 - Regulatory affairs 3.1-3.8.
30. Singh, V. and Mitra, S., 2008. Regulatory management and Reform in India. Consumer unity and Trust Society (CUTS) International, pp.2.1 (Typology regulation in India).
31. Khar, R., Vyas, S., Ahmad, F. and Jain, G., 2021. Lachman/Lieberman's The Theory and Practice of Industrial Pharmacy. 4th ed. CBS Publishers & Distributers Pvt Ltd, pp. Section IV (30) Drug Regulatory Affairs .pp.2496.
32. Kumar, P., Mangla, B., Singh, S. and Rana, A., 2017. Research article on Generic Drug in Global market and regulatory environment. INDO American Journal Of Pharmaceutical Science, 4(12), pp.4716-4717.
33. S, S., Puranik, S. and Patel, P., 2014. An Overview of Regulatory Process for Pharmaceutical Sector in India. Research and Review: Journal of Pharmacy and Pharmaceutical Science, 3(4), p.43.
34. Patel, P., 2015. Drug regulation in India: SWOT Analysis. International Journal of Drug regulatory affairs, 3(3), p.21.